Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

Treatments: Drug: Nivolumab

Study type: Observational

Funder types: Industry

Identifiers

NCT06735781

CA209-1512

Details and patient eligibility

About

The purpose of this study is to evaluate real-world effectiveness of neoadjuvant nivolumab plus chemotherapy in France.

Enrollment: 101 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Having a diagnosis of resectable non-small cell lung cancer (NSCLC)
• Being 18 years or above at the time of their NSCLC diagnosis
• Having initiated a neoadjuvant treatment with nivolumab and chemotherapy outside a clinical trial
• Being indexed in the site database
• Being followed at the site for at least 5 months, except for patients with a record of death

Exclusion criteria

• Having any primary tumor other than NSCLC on or before the date of NSCLC diagnosis that required a treatment ending less than 12-months before the nivolumab plus chemotherapy neoadjuvant treatment

Trial design

101 participants in 1 patient group

Neoadjuvant nivolumab plus chemotherapy treatment

Treatment:

Drug: Nivolumab